TY - JOUR
T1 - Patients’ perceptions of faecal calprotectin testing in inflammatory bowel disease
T2 - results from a prospective multicentre patient-based survey*
AU - Kalla, Rahul
AU - Boyapati, Ray
AU - Vatn, Simen
AU - Hijos, Gonzalo
AU - Crooks, Benjamin
AU - Moore, Gregory Thomas
AU - Hall, Veronica
AU - Lipscomb, George
AU - Gomollón, Fernando
AU - Jahnsen, Jørgen
AU - Singh, Salil
PY - 2018/12
Y1 - 2018/12
N2 - Introduction: Despite its success, there appears to be practical issues with Faecal Calprotectin (FC) testing in Inflammatory Bowel Diseases (IBD), including sample collection, delivery and processing delays. Patients’ perception and barriers to FC testing are yet to be explored in clinical practice. Method: A prospective patient survey was undertaken at IBD units in UK, Europe and Australia. A 9-point patient-based questionnaire was completed in clinic and included demographics, previous FC testing and FC sample difficulty rating score. Predictors of testing difficulty were derived using multivariable logistic regression analysis. Results: A total of 585 patients with IBD completed the survey; 306 males with a median age of 43 years (IQR: 31–54). There were 446 patients (76%) who had prior FC testing experience. Of these, 37% (n = 165) rated FC testing difficult; ‘sample collection’ (n = 106; 67%) being the most common reason reported. Multivariable regression analysis identified age <49 years (odds ratio (OR): 2.5, CI:1.6-4.0), disease duration <35 months (OR 1.4, CI:0.9–2.1) and testing location (UK centre: OR 1.9, CI:1.2-3.1) as predictors of a difficult FC rating score. Conclusions: A total of 37% of patients find FC testing challenging, in particular those aged <49 years, disease duration <35 months. Further studies understanding and addressing these practical issues may aid higher FC uptake in clinic.
AB - Introduction: Despite its success, there appears to be practical issues with Faecal Calprotectin (FC) testing in Inflammatory Bowel Diseases (IBD), including sample collection, delivery and processing delays. Patients’ perception and barriers to FC testing are yet to be explored in clinical practice. Method: A prospective patient survey was undertaken at IBD units in UK, Europe and Australia. A 9-point patient-based questionnaire was completed in clinic and included demographics, previous FC testing and FC sample difficulty rating score. Predictors of testing difficulty were derived using multivariable logistic regression analysis. Results: A total of 585 patients with IBD completed the survey; 306 males with a median age of 43 years (IQR: 31–54). There were 446 patients (76%) who had prior FC testing experience. Of these, 37% (n = 165) rated FC testing difficult; ‘sample collection’ (n = 106; 67%) being the most common reason reported. Multivariable regression analysis identified age <49 years (odds ratio (OR): 2.5, CI:1.6-4.0), disease duration <35 months (OR 1.4, CI:0.9–2.1) and testing location (UK centre: OR 1.9, CI:1.2-3.1) as predictors of a difficult FC rating score. Conclusions: A total of 37% of patients find FC testing challenging, in particular those aged <49 years, disease duration <35 months. Further studies understanding and addressing these practical issues may aid higher FC uptake in clinic.
KW - biomarkers
KW - compliance
KW - Crohn’s disease
KW - Faecal calprotectin
KW - inflammatory bowel disease
KW - survey
KW - ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85057298192&partnerID=8YFLogxK
U2 - 10.1080/00365521.2018.1527394
DO - 10.1080/00365521.2018.1527394
M3 - Article
AN - SCOPUS:85057298192
SN - 0036-5521
VL - 53
SP - 1437
EP - 1442
JO - Scandinavian Journal of Gastroenterology
JF - Scandinavian Journal of Gastroenterology
IS - 12
ER -